North America Contraceptives Market size exceeded USD 5.5 billion in 2021 and is expected to witness 7.3% CAGR from 2022 to 2028. The surging use of contraceptives among the younger adults is anticipated to drive the market revenue.
Get more details on this report - Request Free Sample PDF
Contraception is an approach used for preventing pregnancy by the means of drugs or a device. It is also referred to as birth control or fertility control mechanism. The medications or devices used as contraceptives hamper the normal process of sperm-ovum fertilization to avoid pregnancy. Contraceptives comprises drugs such as oral contraceptive pills, injectable contraceptives, or topical contraceptives; while devices such as condoms, vaginal rings, and diaphragms among others are employed. The rising emphasis directed towards family planning and prevention of unwanted pregnancy is expected to proliferate the market growth.
Adoption of facilitative initiatives by public organizations as well as government authorities is further projected to boost the industry growth. For instance, according to the Global Health Policy, in 2021, the U.S. government promoted the family planning and reproductive health (FP/RH) to increase the use of contraceptives & it is one of the largest distributors of contraceptives. The U.S. government funding for FP/RH surged over the period of time and reached USD 608 million in FY 2020. The improved access to family planning and reproductive health education & services aids in preventing maternal deaths and unintended pregnancies. Similarly, another public organization, the American College of Obstetricians and Gynecologists supports and recommends the use of contraceptives. The organization strives to provide comprehensive contraceptive care and contraceptive techniques as an indispensable part of women’s healthcare. It also encourages upholding policies and initiatives that assures the accessible & cost-efficient contraceptive care.
North America Market, By Product
The devices segment will observe around 8.8% growth rate during the forecast period, due to the rising awareness regarding sexually transmitted diseases (STDs), better success rate offered by contraceptive devices, and the efficacy offered by condoms in preventing the infections, including HIV. Levonorgestrel intrauterine system (LNG IUD) and copper T intrauterine device (IUD) are amongst the increasingly preferred contraceptive devices. These devices are placed in the uterus and releases a small portion of progestin to prevent pregnancy. The rising number of gynecologists preferring for contraceptive devices owing to higher clinical success is further set to fuel the market demand.
North America Market, By Country
U.S. contraceptives market accounted for more than USD 5,233 million revenue in 2021, owing to the increased usage of contraceptives and adoption of conducive policies in the country. For instance, according to the CDC statistics, in 2016, approximately 88% sexually active women were using a contraceptive method. The use of contraceptives among women aged 15-24 years was 83% and surged with age, reaching to 91% among women aged 25–34 year. Also, the availability of publicly supported family planning services under initiatives such as Title X and Medicaid allows women to prevent around 2.2 million unintended pregnancies every year. The implementation of Affordable Care Act in all states that provides a robust package of contraceptive services plays an anchoring role in developing high-quality contraceptive care.
Competitive Industry Landscape
Some of the leading companies operating in the market are Allergan Plc, Bayer Corporation, Cooper Surgical, Inc., Church & Dwight Co., Inc., Mayer Laboratories, Inc., Merck & Co. Inc., Pfizer, Reckitt Benckiser Group Plc, and Teva Pharmaceuticals Industries Ltd.
These prominent players are adopting novel, organic & inorganic strategies such as product launches and mergers & acquisitions for garnering revenue share and strengthening their industrial presence. For instance, in October 2021, Bayer plans to invest more than USD 453 million (EUR 400 million) to increase access to modern contraception. This investment will help the company in expanding their contraceptives portfolio and R&D capabilities.